Publications

ABSTRACT | ASCO 2024

IMM2510, an anti-PD-L1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: A phase I dose-escalation study.

POSTER | ASCO 2023

Preliminary results of a phase I dose escalation study of IMM2510, a PD-L1 and VEGF bispecific fusion protein, in patients with advanced tumors

POSTER | SITC ANNUAL MEETING, NOVEMBER 3-5 2023

Anti-folate receptor alpha (FRα) CoStimulatory Antigen Receptor (CoStAR™) drives distinct cytokine-mediated proliferation responses in CD4+ and CD8+ T cells.

POSTER | SITC ANNUAL MEETING, NOVEMBER 3-5 2023

Single cell RNA sequencing reveals functionally validated signatures of cytotoxicity in anti-FRá CoStimulatory Antigen Receptor (CoStAR™) activated CD4+ T cells.

PRESENTATION | BSGCT ANNUAL CONFERENCE, JUNE 22-23, 2023

A CD28/CD40 based chimeric costimulatory antigen receptor (CoStAR™) targeting folate receptor alpha enhances anti-tumour activity of tumour infiltrating lymphocytes

POSTER | SITC ANNUAL MEETING, NOVEMBER 8-12, 2022

Anti-folate Receptor Alpha (FRα) CoStimulatory Antigen Receptor (CoStAR™) Improves T-cell Function Across Physiologically Relevant Ranges of FRα Expression and T-cell Receptor Affinities

POSTER | SITC ANNUAL MEETING, NOVEMBER 8-12, 2022

ITIL-306-201: A Multicenter, First-in-Human Phase 1a/1b Study of ITIL-306, an Engineered Autologous TIL Cell Therapy Product, in Adults With Advanced Solid Tumors

MANUSCRIPT | American Journal of Cancer Research, August 30, 2022

Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma

POSTER | ASCO ANNUAL MEETING, JUNE 3-7 2022

Antitumor activity of T cells expressing a novel anti-FOLR1 CoStAR in a human xenograft murine solid tumor model and implications for in-human studies

PRESENTATION | ASGCT ANNUAL MEETING, MAY 18, 2022

Characterization of the Transcriptomic and T-Cell Receptor (TCR) Clonal Heterogeneity of Tumor-Infiltrating Lymphocyte (TIL) Therapy Infusion Products by Single-Cell Sequencing and Correlative Analyses With Clinical Efficacy in Patients With Advanced Cutaneous Melanoma (ASGCT)

Poster | SITC Annual Meeting, Nov. 12-14, 2021

Costimulatory Antigen Receptor (CoStAR): A Novel Platform That Enhances the Activity of Tumor-Infiltrating Lymphocytes (SITC)

Poster | SITC Annual Meeting, Nov. 12-14, 2021

DELTA 1: A Global, Multicenter, Phase 2 Study of ITIL-168, an Unrestricted Autologous Tumor-Infiltrating Lymphocyte Cell Therapy, in Adult Patients With Advanced Cutaneous Melanoma (SITC)

Poster | SITC Annual Meeting, Nov. 12-14, 2021

Potent T-Cell Costimulation Mediated by a Novel Costimulatory Antigen Receptor (CoStAR) With Dual CD28/CD40 Signaling Domains to Improve Adoptive Cell Therapies (SITC)

Poster | ESMO Congress, Sep. 16-21, 2021

Treatment Outcomes With Unselected Autologous Tumor-Infiltrating Lymphocytes in Patients With Checkpoint Inhibition–Refractory Advanced Cutaneous Melanoma (ESMO)

Poster | AACR Annual Meeting, April 9-14 2021

Clinical Feasibility and Treatment Outcomes With Unselected Autologous Tumor Infiltrating Lymphocyte Therapy in Patients With Advanced Cutaneous Melanoma (AACR PPT)

Poster | AACR Annual Meeting, April 9-14 2021

Clinical Feasibility and Treatment Outcomes With Unselected Autologous Tumor Infiltrating Lymphocyte Therapy in Patients With Advanced Cutaneous Melanoma (AACR ePoster)

May 2020

Massively parallel interrogation and mining of natively paired human TCRαβ repertoires

December 2019

Efficacy of adoptive therapy with tumor-infiltrating lympohocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis

November 2019

CoStAR (Costimulatory Antigen Receptor) enhancement of tumor infiltrating lymphocyte Therapy

November 2018

In vitro analysis of tumor infiltrating lymphocytes engineered with costimulatory antigen receptors delivering targeted costimulation